Prices are leveling, but the real story is where competitive edge is moving: from rebates and discounts to experience, trust, and the moments that keep a patient on therapy. We dig into the MFN pricing model and its ripple effects across U.S. pharma, explaining how reference-based pricing compresses margins and forces brands to compete on loyalty, adherence, and the quality of their support programs. When physicians and patients see real-time costs at the point of prescribing, “comparable” op...
All content for Postscripts Rx is the property of PostScripts Rx Team and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Prices are leveling, but the real story is where competitive edge is moving: from rebates and discounts to experience, trust, and the moments that keep a patient on therapy. We dig into the MFN pricing model and its ripple effects across U.S. pharma, explaining how reference-based pricing compresses margins and forces brands to compete on loyalty, adherence, and the quality of their support programs. When physicians and patients see real-time costs at the point of prescribing, “comparable” op...
Why Pharma Is Investing Back in the U.S.—And What It Means for Your Medicine
Postscripts Rx
5 minutes
1 month ago
Why Pharma Is Investing Back in the U.S.—And What It Means for Your Medicine
Policy sparks the shift, but patients feel the impact—faster access, steadier supply, and smarter support. We dig into why major pharma players are pouring billions into U.S. manufacturing, how most favored nation pricing is reshaping reimbursement strategy, and where digital medication tools close the gap between a written script and a successful outcome. With examples like Eli Lilly’s Texas investment and Pfizer’s recent pricing moves, we map the real-world changes that determine whether yo...
Postscripts Rx
Prices are leveling, but the real story is where competitive edge is moving: from rebates and discounts to experience, trust, and the moments that keep a patient on therapy. We dig into the MFN pricing model and its ripple effects across U.S. pharma, explaining how reference-based pricing compresses margins and forces brands to compete on loyalty, adherence, and the quality of their support programs. When physicians and patients see real-time costs at the point of prescribing, “comparable” op...
